Cobra to make protein vaccine for Pharmexa
UK-based Cobra Biomanufacturing is to manufacture a protein vaccine for use in Phase I clinical trials for bone disorders for immunotherapy and vaccines developer Pharmexa. The programme will include cell banking, process development and GMP manufacture.
UK-based Cobra Biomanufacturing is to manufacture a protein vaccine for use in Phase I clinical trials for bone disorders for immunotherapy and vaccines developer Pharmexa. The programme will include cell banking, process development and GMP manufacture.
The therapeutic vaccine, PX107, makes use of Pharmexa's proprietary active immunotherapy technology, AutoVac. Currently in preclinical development, PX107 induces a potent polyclonal antibody response towards the protein RANKL, which is increased or imbalanced in the body in diseases such as osteoporosis, rheumatoid arthritis and bone metastasis with pathological bone destruction.
Pharmexa which has operations in Denmark, Norway and the US, will carry out the upstream and downstream development of PX107 but it requires Cobra's cGMP manufacturing capabilities to produce the material for clinical Phase I trials.
Cobra, has GMP manufacturing facilities in both Keele and Oxford, UK and David Thatcher, chief executive of Cobra, said this product will be manufactured at its recently expanded Oxford site. The UK company provides manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products and was among the first to develop GMP standard DNA manufacture in Europe.